Equites Radar

ELAN · Elanco Animal Health Incorporat

Drug Manufacturers - Specialty & GenericUnited StatesAnalyst view: Strong Buy

$24.91

+0.43% last session

End-of-day data · updated 2026-07-28

Bullish4 bullish · 1 bearish technical signals
Consensus: Strong Buy (1.41 from 14 analysts)
To mean target: +20.7%

Market cap

$13B

Enterprise value

$17B

Trailing P/E

Forward P/E

21.2

Dividend yield

Beta

1.68

Avg volume

6M

Employees

9K

2D change

5D change

2.54%

10D change

-1.63%

30D change

3.42%

60D change

6.54%

MTD change

5.48%

YTD change

12.28%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.41
Covering analysts14
Mean price target$30.07
Low price target$26.00
Upside to mean target+20.7%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)56.7
50-day MA$23.94
200-day MA$23.34
Price vs 50-day MA+6.6%
Price vs 200-day MA+9.3%
MACD histogram-0.05
Volume vs 3-month avg0.6×
52w low $13.6852w high $26.84

Analyst sentiment over time — ELAN

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-22

Latest call per bank · past 12 months

Morgan Stanley

Equal-Weight

$26.00

+4.4% vs price
▲ raised from $23.00Maintains · 2026-07-22

Citigroup

Buy

$31.00

+24.4% vs price
▲ raised from $30.00Maintains · 2026-05-07

JP Morgan

Overweight

$30.00

+20.4% vs price
▲ raised from $28.00Maintains · 2026-05-07

Barclays

Overweight

$30.00

+20.4% vs price
▲ raised from $0.00Initiates · 2025-12-09

UBS

Buy

$27.00

+8.4% vs price
▲ raised from $25.00Maintains · 2025-11-06

Recent rating actions

DateFirmActionRatingPrice target
2026-07-22Morgan StanleyMaintainsEqual-Weight$23.00 $26.00
2026-06-18TD CowenMaintainsBuy$31.00 $32.00
2026-05-07CitigroupMaintainsBuy$30.00 $31.00
2026-05-07JP MorganMaintainsOverweight$28.00 $30.00
2026-04-15CitigroupInitiatesBuy$0.00 $30.00
2026-02-25Morgan StanleyMaintainsEqual-Weight$22.00 $24.00
2026-02-25KeybancMaintainsOverweight$27.00 $29.00
2026-02-24Leerink PartnersMaintainsOutperform$26.00 $30.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 6.6% above the 50-day MA ($23.94).
  • Price vs 200-day MA: Trading 9.3% above the 200-day MA ($23.34).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
  • 52-week range: Price is within 5% of the 52-week high ($26.84).

ELAN Price Chart

Loading chart for ELAN

Fundamentals

Revenue (TTM)$5.0B
EBITDA$1.0B
Free cash flow$1.0B
Operating cash flow$1.0B
Book value / share$13.02
Net debt / EBITDA4.0
WACC13.0%
Revenue growth15.00%
Earnings growth-15.00%

About Elanco Animal Health Incorporat

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

More in Drug Manufacturers - Specialty & Generic

Screen ELAN against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.